metabolic disorders

PAL-4 stimulates the activity of LYPLAL1, a poorly characterized serine hydrolase with complex genetic links to human metabolic traits.

Azelaprag (AMG 986) is an oral apelin receptor agonist (EC50 = 0.32 nM). Azelaprag may be used to treat neurological disorders, cardiovascular diseases, and obesity with metabolic syndrome.

AZD-8055 is an orally bioavailable, highly selective, ATP-competitive mTOR kinase inhibitor that directly binds to the ATP-binding pocket of the mTOR kinase domain, while potently inhibiting both mTORC1 and mTORC2 complexes (IC₅₀ values of 0.8 nM and 0.1 nM, respectively). AZD-8055 is suitable for research in oncology, metabolic diseases, and fibrotic disorders.

Tirzepatide sodium is the sodium salt form of a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist peptide drug that enhances insulin secretion and improves glycemic control by simultaneously activating GIP and GLP-1 receptors. In research and clinical settings, Tirzepatide sodium has also demonstrated effects in reducing body weight and improving metabolic parameters, and is used in studies related to type 2 diabetes and metabolic disorders.

Amibegron hydrochloride is a selective β3-adrenergic receptor (β3AR) agonist that increases energy expenditure and fat oxidation by activating β3ARs in brown adipose tissue; Amibegron hydrochloride is commonly used in research on metabolic disorders. Amibegron hydrochloride exhibits anxiolytic and antidepressant activity.

RPR107393 free base is a selective and potent inhibitor of squalene synthase (SQS) for the study of neurological disorders and endocrine and metabolic disorders.

SR10067 is a potent, selective, and brain-penetrant agonist of Rev-Erbβ (IC50 = 160 nM) and Rev-Erbα (IC50 = 170 nM) with anxiolytic activity.

Tiludronate disodium (Tiludronic acid disodium) is an osteoclast vacuolar H(+)-ATPase inhibitor with antiresorptive and anti-inflammatory properties. Tiludronate disodium can be used in studies about metabolic bone disorders.

SPD-473 citrate (BTS 74398 citrate) is a dopamine reuptake inhibitor, a norepinephrine transporter protein (NET) inhibitor, and a 5-hydroxytryptamine reuptake inhibitor, and is used in the study of neurological disorders and endocrine and metabolic diseases.

6-Chloromelatonin is a potent melatonin receptor agonist, a 5-methoxyindole compound that competes for presynaptic melatonin receptor sites in the rabbit retina, inhibiting the calcium-dependent release of [3H]dopamine with higher metabolic stability than melatonin. Chloromelatonin competitively binds to [3H]melatonin at MT2 receptors (pKi=9.77) and may be used to study insomnia and sleep disorders associated with depression.

SB 216641 hydrochloride (SB-216641A) is a selective 5-HT₁B/D receptor antagonist with binding affinities (K_i) of 0.9 nM and 1.8 nM for human and rat 5-HT₁B receptors, respectively. SB 216641 hydrochloride is primarily used in studies of 5-HT₁B-mediated neuroregulation, migraine, anxiety, and vascular responses.

PS423 (PS210AM) is a substrate-selective inhibitor of PDK1 and a selective PDK1 activator that inhibits the phosphorylation and activation of S6K, and is used in the study of endocrine and metabolic disorders.

Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.

Eldacimibe (WAY-ACA-147) is an ACAT2 inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, study of atherosclerosis and hypercholesterolemia.

Miricorilant (CORT 118335) is a selective glucocorticoid receptor modulator for the study of digestive and metabolic disorders.

Ronacaleret HCl (SB-751689) is a small molecule CaSR antagonist for the treatment of endocrine and metabolic diseases, skin and musculoskeletal disorders.

11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively. 11β-Hsvd1-in-11 is a compound used as a chemical compound. 11β-HSD1-IN-11 is a hormone involved in regulating various physiological processes, such as metabolism, inflammation, and stress responses. 11β-Hd1-in-11 is a potential compound for the treatment of metabolic disorders, obesity, and certain inflammatory conditions.

Hepcidin antagonist-1 is an iron-modulating antagonist.Hepcidin antagonist-1 can be used to study metabolic disorders such as iron-deficiency diseases and anemia.

Quercetin-3'-o-phosphate TEA (Quercetin 3'-phosphate TEA) is an adenosine A receptor antagonist that can be used to prevent and treat metabolic disorders.

(S)-VU0637120 is a selective neuropeptide Y(4)R-mutant antagonist used in the study of metabolic disorders.

LI-2242 is a potent inositol hexakisphosphate kinase (IP6K) inhibitor with IC50s of 31 nM, 42 nM, 8.7 nM, and 1944 nM for IP6K1, IP6K2, IP6K3, and IPMK, respectively.LI-2242 ameliorated hepatic steatosis by reducing the expression of genes that enhance lipid uptake, lipid stabilization, and adipogenesis, and enhanced mitochondrial oxygen consumption rate (OCR) and insulin signaling in adipocytes and hepatocytes in vitro. LI-2242 ameliorated diet-induced obesity, hyperglycemia and hepatic steatosis in mice.LI-2242 can be used to study type II diabetes, obesity, metabolic complications, venous thrombosis and psychiatric disorders.

JBSNF-000028 belongs to small molecule inhibitors, serving as a nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=33 nM (human), 190 nM (monkey), 210 nM (mouse)), with oral activity and cell permeability, for research on metabolic disorders, possessing insulin-sensitizing, glucose-lowering, and weight-reducing effects.

Phanginin A, a natural product discovered in Caesalpinia sappan Linn, activates SIK1 and inhibits gluconeogenesis in mouse primary hepatocytes. Phanginin A increases PDE4 activity and suppresses the hepatic cAMP/PKA/CREB pathway, improving metabolic disorders in ob/ob mice. It may be used in studies of type 2 diabetes.

PF-07328948 is a branched-chain keto acid dehydrogenase kinase (BDK) inhibitor, useful in research on cardiovascular disease (CVD) and metabolic disorders.